← All organizations

Madrigal Pharmaceuticals

For profitContributed to NMEWebsite ↗

Also known as: MADRIGAL | Madrigal Pharmaceuticals, Inc.

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 3

First clinical trial

First marketed drug

First NDA

Last known activity

Mar 14, 2024

Timeline

2010s

Jun 1, 2011
Madrigal Pharmaceuticals— Founded
Apr 14, 2016
Synta Pharmaceuticals Corp.— Acquired

2020s

Mar 14, 2024
resmetirom— NDA Organization

Drugs by trial phase (21 distinct, 55 trials)

Phase 3 (2 own, 4 via acquisition)

Phase 2 (0 own, 4 via acquisition)

Phase 1 (5 own, 6 via acquisition)

Indications

Studied for

Marketed drugs (1)

resmetirom

Subsidiaries (1 direct, 1 total across the full acquisition tree)

Synta Pharmaceuticals Corp.

Recent trials (22)

NCT06397872OfficialPhase 1Mar 5, 2024
NCT06397872Lead sponsorPhase 1Mar 5, 2024
NCT05500222Lead sponsorPhase 3Aug 26, 2022
NCT04951219Lead sponsorPhase 3Jul 9, 2021
NCT04951219Study directorPhase 3Jul 9, 2021
NCT04197479Lead sponsorPhase 3Dec 31, 2019
NCT04197479Study directorPhase 3Dec 31, 2019
NCT04671069Lead sponsorPhase 1Jul 26, 2019
NCT03900429Study directorPhase 3Mar 28, 2019
NCT03900429Lead sponsorPhase 3Mar 28, 2019
NCT04671056Lead sponsorPhase 1Nov 9, 2018
NCT04643795Lead sponsorPhase 1Oct 24, 2018
NCT03413124Lead sponsorPhase 1Feb 5, 2018
NCT03220165Lead sponsorPhase 1Aug 6, 2017
NCT03038022Lead sponsorPhase 2Feb 1, 2017

Details

Founded: Washington, PA, US Jun 1, 2011
First NDA: Mar 14, 2024
Last known activity: Mar 14, 2024

Designations held

Fast track
Priority review
Breakthrough therapy
Accelerated approval